Understanding how BMP9 signaling affects lung transplant outcomes
Official title: Dissecting the role of vascular endothelial BMP9 signaling in lung transplantation
Funded at Northwestern University at Chicago · NIH-10996899 · Data updated 2026-11-12
This study is looking at how a special protein called BMP9 might help improve lung transplant outcomes by reducing damage that can happen during the surgery, which affects many patients, and it hopes to find new ways to make lung transplants safer and more successful.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | February 6, 2025 |
| Project end | February 5, 2027 |
| Funding year | 2024 |
| Award (this year) | $44,187 |
| NIH project number | 1F31HL176117-01 |
| Project ID | NIH-10996899 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are undergoing or have undergone lung transplantation and are at risk for primary graft dysfunction.
✕Less likely to help
Patients who have not undergone lung transplantation or those with chronic lung diseases unrelated to transplant may not benefit from this research.
What this research studies
This research investigates the role of bone morphogenetic protein 9 (BMP9) signaling in lung transplantation, particularly focusing on primary graft dysfunction (PGD), which affects 30% of lung transplant recipients. The study aims to understand how ischemia reperfusion injury (IRI) impacts lung microvasculature and contributes to PGD. By using both in vitro and in vivo models, the researchers will explore whether enhancing BMP9 signaling can mitigate the harmful effects of IRI and improve lung transplant outcomes. This could lead to new therapeutic strategies for patients undergoing lung transplantation.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the survival and quality of life for lung transplant patients.
How similar studies have gone: While BMP signaling has been studied in other lung injuries, this specific investigation into its role in lung transplantation and PGD is novel and has not been previously tested.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Gill, Blake — Northwestern University at Chicago
- Study coordinator: Gill, Blake
Related research
Other NIH-funded projects on the same topics.
-
Body composition and outcomes after lung transplant
A patient-focused look at how body fat and muscle measurements around the time of lung transplant relate to recovery, complications, and quality of life after surgery.
-
Objective lung-donor quality tools to expand the transplant pool
A lung-transplant-focused project aims to use gene-based risk tools to better judge donor organs and prevent recipient lung dysfunction.
-
Bmp-Cx40 signaling to keep lung blood vessels calm after transplant
A study aims to keep blood vessels in transplanted lungs stable by boosting a specific signaling pathway to reduce injury after transplant.
-
Complement inhibition to protect transplanted lungs from early injury
A small early trial tests whether a drug that blocks a key part of the immune system can prevent damage to new lungs right after transplant.
-
Phase 1 trial of siltuximab for antibody-mediated rejection after lung transplant
A early-stage study tests whether siltuximab can help people who have antibody-mediated rejection after lung transplantation.
-
Targeted delivery of immune-suppressing agents to the lung graft to prevent rejection
A study at Northwestern University will test a new, targeted approach to prevent lung transplant rejection by delivering immune-suppressing drugs directly to the graft while blocking early signals that trigger rejection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.